HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stop aggressive lymphomas from coming back
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. About 363 adults with these aggressive lymphomas will receive either the usual chemo or the usual chemo plus venetoclax. The goal is …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New hope for aggressive lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. The goal is to find the best dose and see if the combination is safe and works better than standard treatment alone. Ab…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could an oral drug boost chemo for seniors with lymphoma?
Disease control OngoingThis study looks at whether adding an oral medication (CC-486, or oral azacitidine) to a standard reduced-dose chemo regimen (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas. The goal is to see if the combination improves how long pa…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:53 UTC